O citrato de sildenafil (viagra®) inibe a motilidade gastrintestinal em ratos acordados e anestesiados e a contratilidade in vitro de tiras isoladas de duodeno de ratos ex vivo

Detalhes bibliográficos
Ano de defesa: 2005
Autor(a) principal: Graça, José Ronaldo Vasconcelos da
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Não Informado pela instituição
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: http://www.repositorio.ufc.br/handle/riufc/4036
Resumo: We evaluated the effect of sildenafil citrate (Viagra®) a vasodilator largely used for the treatment of male erectile dysfunction, on the gastrointestinal motility in rats. Experiments were performed on 175 male, Wistar rats, weighing 200-350g. Four groups of study were done: the sildenafil effects on the: i) Gastric emptying (GE) and gastrointestinal (GI) transit and ii) Intestinal transit (IT) of liquid in awake rats; iii) Gastric compliance in anesthetized rats and iv) Contractility of rat duodenal isolated strips. i) In 64 rats fasted for 24h with previous vascular access (right jugular vein and left carotid artery), we studied the effect of an i.v. injection (0.2mL) of sildenafil (4mg/Kg) or vehicle (0.01N HCl) on GE and GI transit of a liquid meal, as well as on arterial pressure (AP) in a separated group of rats. Animals were gavage-fed with 1.5mL of a test meal (0.5mg/mL of phenol red in 5% glucose). After 10, 20 or 30min, animals were sacrificed and submitted to a laparotomy to obstruct the pylorus, cardia and terminal ileus. The gut was removed and then divided into: stomach and consecutive three small intestine segments (40% proximal; 30% medial and 30% terminal). After processing these segments, the dye retention was determined at 560nm. The percentage of dye retention in each segment permitted to evaluate GE and GI transit. Arterial pressure was continuously monitored by a digital acquisition system during 20min before and 30min after sildenafil injection. We observed a significant increase of gastric retention in sildenafil treated rats at 10, 20, or 30min after the test meal (44,2±2,0 vs 53,2±2,1; 25,4±1,3 vs 37,3±1,6; 20,9±2,5 vs 32,5±2,9%, respectively), as well as a significant GI transit delay. Despite of sildenafil inducing hypotension, AP returned to basal levels 10min afterwards. Acid gastic secretion blocking pre-treatment with omeprazol did not modify the sildenafil effect on gastric retention, GI transit or AP. ii) In another group we evaluated the sildenafil (4mg/Kg) or diluente (0.01N HCl, 0.2mL) effects on the IT in awake rats, fasted for 24h. Animals were studied 3d after the insertion of a silastic cannula (0.6cm ID) into the duodenal bulb. We evaluated the progression of a radioactive liquid test meal fed (10MBq of 99mTc – 1mL of saline 0,9%) administered through the inserted cannula into the small intestine. After 20, 30 or 40min, animals were sacrificed by anesthetic overdose. After laparotomy, we removed and divided the gut in: stomach, five congruent and consecutive segments of the small intestine and the large intestine. Radioactivity counting was obtained in a gamma-chamber collimator. Sildenafil promoted an IT delay (p<0.05), indicated by shifting the center of mass to the proximal portions of the TGI (2.8±0.2 vs 3.3±0.1; 3.0±0.2 vs 3.7±0.1 and 3.4±0.1 vs 4.2±0.2) in relation to control group. iii) Gastric compliance study was performed on 39 anesthetized rats after 24h of fasting. Gastric volume (GV) variations were measured by plethysmography while AP was continuously monitored. We have also observed that GV increased (p<0.05) after sildenafil treatment (3mg/Kg - e.v) (3.08±0.18; 3.10±0.17 and 3.09±0.17mL vs 2.91±0.19mL) at 10, 20 and 30min after drug administation, respectively. Basal AP (105.8±2.28mmHg) dropped by the sildenafil injection (59.8±3.2; 64.8±3.7 and 59.3±4.6mmHg-p<0.05) while vehicule (0.01N HCl) did not change either GV or AP. After splanchnotomy or pre-treatments (e.v.) with methylene blue (3mg/Kg-guanilate cyclase blocker), L-NNA (3mg/Kg - NO synthase blocker) or propranolol (2mg/Kg - ß-blocker) prevented GV increase due to sildenafil; while post-treatment with sodium nitroprusside (1mg/Kg - NO donor) raised it. iv) The in vitro contractility studies were performed on isolated duodenal strips obtained from rats (n=28) killed by cervical dislocation. Duodenal strips were suspended longitudinally in a glass chamber (10mL), filled with Tyrode solution (37oC and pH 7.4). After 1h of stabilization under 1g of initial tension, the spontaneous or induced contractility were continuously recorded by a digital acquisition system. Increasing and cummulative doses of sildenafil (0.1 to 300µmol/L) relaxed (9.6µmol/L of EC50) the duodenal strips. This effect was more intense than those displayed by zaprinast or papaverine (PDEs blockers) (91.6 and 78.5µmol/L of EC50, in this order). Sildenafil showed significant antispasmodic and myorelaxant effects on the duodenal contractions induced by acetylcholine or carbamylcholine (IC50 26.7 and 16.2µmol/L, respectively). Pre-treatment with methylene blue, ODQ (guanilato cyclase blocker) or L-NAME (NO synthase blocker) also prevented these sildenafil effects, but D-NAME (an inactive substrate for NO synthase) did not. Myorelaxant sildenafil effect was reverted by L-arginine (substrate for NO synthase) and contrarily it was largely increased by sodium nitroprusside. Forskolin adenylate cyclase activation pre-treatment also increased the myorelaxant effect of sildenafil. In summary, we have observed that sildenafil slowed down the gastrointestinal motility, delaying GE, GI and intestinal transits of a liquid meal in awake rats; Gastric compliance was also increased in anesthetized rats treated with sildenafil. Sildenafil also exhibited both antispasmodic and myorelaxant effects on isolated strips of duodenum of ex vivo rats. Besides central or peripheral sympathetic nervous system activation, sildenafil possibly acts at the gastrointestinal myocite level by activating the NO/GMPc system.